{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008761","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.720707+00:00","generated_at":"2026-06-17T23:06:57.480335+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Graphite Bio discontinues sickle cell gene therapy nula-cel, begins strategic review, reports FY2022 net loss $101.1M","bullets":["Discontinued development of nula-cel for sickle cell disease after serious adverse event (pancytopenia) in first dosed patient.","Initiated process to evaluate strategic alternatives; corporate restructuring to preserve capital while conducting review.","FY2022 net loss $101.1M ($1.84/share); cash and equivalents $283.6M as of Dec 31, 2022.","Voluntarily paused Phase 1/2 CEDAR study of nula-cel in Jan 2023 due to treatment-related pancytopenia.","Intends to continue research on early-stage non-genotoxic conditioning program toward potential development candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008761","json":"https://secwatch.observer/filing/0000950170-23-008761.json","markdown":"https://secwatch.observer/filing/0000950170-23-008761.md","text":"https://secwatch.observer/filing/0000950170-23-008761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/0000950170-23-008761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/grph-20230320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:06:57.480335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e9a7a02583e8bb2f97a3ceec8208c01972032ab","claim":"LENZ Therapeutics, Inc. reported Fourth quarter and fiscal year 2022 results: net income Net loss was $24.6 million for the fourth quarter of 2022; Net loss was $101.1 million for fiscal year 2022, EPS $0.44 per basic and diluted share for the fourth quarter of 2022; $1.84 per basic and diluted share for fiscal year 2022.","evidence_excerpt":"Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/0000950170-23-008761-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth quarter and fiscal year 2022"},{"label":"Net income","value":"Net loss was $24.6 million for the fourth quarter of 2022; Net loss was $101.1 million for fiscal year 2022"},{"label":"EPS","value":"$0.44 per basic and diluted share for the fourth quarter of 2022; $1.84 per basic and diluted share for fiscal year 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}